H-CMTWNQMNL-OH

Ref. 3D-PP46332

Información del producto

• Nombre: H-CMTWNQMNL-OH
• Sinónimos: NH2-Cys-Met-Thr-Trp-Asn-Gln-Met-Asn-Leu-OH

Descripción

Peptide H-CMTWNQMNL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-CMTWNQMNL-OH include the following: Computational analysis on the binding of epitope peptide to human leukocyte antigen class I molecule A* 2402 subtype Y Matsuo, S Neya, T Hoshino - Chemical and Pharmaceutical , 2011 - jstage.jst.go.jphttps://www.jstage.jst.go.jp/article/cpb/59/10/59_10_1254/_article/-char/ja/ Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes T Tsuji , M Yasukawa , J Matsuzaki , T Ohkuri - Blood, 2005 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/106/2/470/21350 Peptide vaccines for myeloid leukaemias T Dao, DA Scheinberg - Best Practice & Research Clinical Haematology, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1521692608000510 Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes T Azuma, M Makita, K Ninomiya, S Fujita - British journal of , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1046/j.0007-1048.2001.03329.x Establishment of a stable T lymphoma cell line transduced with HLA-A∗ 24: 02-restricted WT1-specific TCR genes and its application to antigen-specific K Watanabe, S Toji, J Ohtake, K Nakano - Biomedical , 2013 - jstage.jst.go.jphttps://www.jstage.jst.go.jp/article/biomedres/34/1/34_41/_article/-char/ja/ Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL I Bellantuono , L Gao, S Parry, S Marley - Blood, The Journal , 2002 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/100/10/3835/106272 WT1 (WILM'S TUMOR GENE) PEPTIDE CANCER VACCINE H Sugiyama - RECENT ADVANCES IN CANCER IMMUNOTHERAPY - ptcrf.or.jphttps://www.ptcrf.or.jp/academic/file/extended_abstract/2014_45extended_abstracts.pdf#page=100 Immunotherapy with chimeric antigen receptor targeting intracellular WT1 gene product complexed with HLA-a* 24: 02 molecule H Ikeda , Y Akahori, M Yoneyama, Y Orito, Y Miyahara - Blood, 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497118512829 Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1+ leukemias E Doubrovina, T Carpenter, D Pankov - Blood, The Journal , 2012 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/120/8/1633/30848 WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases A Tsuboi, Y Oka, T Osaki, T Kumagai - Microbiology and , 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1348-0421.2004.tb03503.x Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A* 2402-binding residues A Tsuboi, Y Oka, K Udaka, M Murakami - Cancer Immunology , 2002 - Springerhttps://link.springer.com/article/10.1007/s00262-002-0328-9 Induction of HM1. 24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma A Jalili, S Ozaki, T Hara, H Shibata, T Hashimoto - Blood, 2005 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/106/10/3538/20945

• Marca: Biosynth